Exagen (XGN) Stock Price, News & Analysis

Company Overview

Exagen Inc. develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; and AVISE Anti-CarP test, which identifies RA patients with severe disease. Further, the company offers AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop novel patented biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.

Key Stats

• Today's Range: $3.04 to $4.09
• 50-Day Range: $2.75 to $6.00
• 52-Week Range: $1.30 to $6.22
• Volume: 814,680 shs
• Average Volume: 173,484 shs
• Market Capitalization: $70.38 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $7.50
• Consensus Rating: Buy

Exagen Stock Analysis - MarketRank™

Exagen scored higher than 95% of companies evaluated by MarketBeat, and ranked 52nd out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Exagen has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Exagen has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Exagen are expected to grow in the coming year, from ($0.87) to ($0.70) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Exagen is -4.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Exagen is -4.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Exagen has a P/B Ratio of 3.00. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.90% of the float of Exagen has been sold short.

Short Interest Ratio / Days to Cover

Exagen has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Exagen has recently increased by 1.41%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Exagen does not currently pay a dividend.

Dividend Growth

Exagen does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.5 / 5
• Environmental Score: -1.29

Percentage of Shares Shorted

0.90% of the float of Exagen has been sold short.

Short Interest Ratio / Days to Cover

Exagen has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Exagen has recently increased by 1.41%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: 0.56

News Sentiment

Exagen has a news sentiment score of 0.56. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.44 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Exagen this week, compared to 1 article on an average week.

Search Interest

1 people have searched for XGN on MarketBeat in the last 30 days.

MarketBeat Follows

Only 3 people have added Exagen to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 5.0 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Exagen insiders have sold 866.37% more of their company's stock than they have bought. Specifically, they have bought $68,297.00 in company stock and sold $660,000.00 in company stock.

Percentage Held by Insiders

26.10% of the stock of Exagen is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

75.25% of the stock of Exagen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

XGN Stock Analysis - Frequently Asked Questions

How have XGN shares performed this year?

Exagen's stock was trading at $4.10 at the beginning of 2025. Since then, XGN stock has decreased by 2.7% and is now trading at $3.99.
View the best growth stocks for 2025 here.

How were Exagen's earnings last quarter?

Exagen Inc. (NASDAQ:XGN) announced its quarterly earnings results on Tuesday, November, 12th. The company reported ($0.28) EPS for the quarter, beating the consensus estimate of ($0.30) by $0.02. The company earned $12.51 million during the quarter, compared to analyst estimates of $13.55 million. Exagen had a negative trailing twelve-month return on equity of 92.58% and a negative net margin of 30.36%.

When did Exagen IPO?

Exagen (XGN) raised $50 million in an initial public offering (IPO) on Thursday, September 19th 2019. The company issued 3,300,000 shares at $14.00-$16.00 per share. Cowen, Cantor and William Blair served as the underwriters for the IPO.

How do I buy shares of Exagen?

Shares of XGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Exagen own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Exagen investors own include Chemours (CC), Ovintiv (OVV), Himax Technologies (HIMX), ImmunoGen (IMGN), Cassava Sciences (SAVA), CNX Resources (CNX) and Ford Motor (F).

Company Calendar

• Last Earnings: 11/12/2024
• Today: 1/20/2025
• Next Earnings (Estimated): 3/17/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Medical laboratories
• Sub-Industry: Healthcare
• Current Symbol: NASDAQ:XGN
• CUSIP: N/A
• CIK: 1274737
• Web: www.exagen.com
• Phone: 760-560-1501
• Fax: N/A
• Employees: 220
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $7.50
• High Stock Price Target: $8.00
• Low Stock Price Target: $7.00
• Potential Upside/Downside: +88.0%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.94)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-23,690,000.00
• Net Margins: -30.36%
• Pretax Margin: -30.30%
• Return on Equity: -92.58%
• Return on Assets: -33.74%

Debt

• Debt-to-Equity Ratio: 1.54
• Current Ratio: 4.05
• Quick Ratio: 4.05

Sales & Book Value

• Annual Sales: $52.55 million
• Price / Sales: 1.34
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.33 per share
• Price / Book: 3.00

Miscellaneous

• Outstanding Shares: 17,640,000
• Free Float: 13,034,000
• Market Cap: $70.38 million
• Optionable: Optionable
• Beta: 1.42